Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis
ABSTRACT Background Pruritus is a common and burdensome symptom in patients with primary sclerosing cholangitis ( PSC ). Aims To determine the prevalence of pruritus in PSC , its clinical associations, and its impact on quality of life. Methods Patients with PSC were assessed for pruritus using the Worst Itch Numerical Rating Scale ( WI ‐ NRS ) and 5‐D Itch scale, and for quality of life using SF ‐36 and PSC ‐ PRO . Participants reporting moderate to severe pruritus ( WI ‐ NRS ≥ 4) within 6 months of enrollment completed longitudinal assessments for up to 6 months. Those with inflammatory bowel disease ( IBD ) completed the Simple Clinical Colitis Activity Index (P‐ SCCAI ). Results Median age was 43 years, 61% were male and 75% had IBD . Moderate to severe itch over the prior 7 days was reported by 24%, increasing to 38% over the prior 6 months. Greater pruritus was associated with cirrhosis ( p = 0.01), alkaline phosphatase ( p = 0.0001), total bilirubin ( p = 0.0006) and lower albumin ( p = 0.01). Among patients with IBD , itch severity was associated with colitis activity ( p = 0.01). Pruritus associated with impaired quality of life on the SF ‐36 ( r s = −0.47) and PSC ‐ PRO ( r s = 0.69). Longitudinally, pruritus varied markedly with 86.5% of patients reporting moderate to severe pruritus in the past 6 months experiencing severe itch at least once over 6 months. Conclusions Pruritus is common, clinically meaningful and fluctuates over time in PSC . Its strong impact on quality‐of‐life underscores the need for standardized assessment and development of more effective therapies.
Authors
- Craig Lammert (ORCID: https://orcid.org/0000-0003-3809-640X)
- Christopher L. Bowlus (ORCID: https://orcid.org/0000-0002-3906-6811)
- Megan McLaughlin (ORCID: https://orcid.org/0000-0002-9259-2984)
- Stuart C. Gordon (ORCID: https://orcid.org/0000-0001-8666-3849)
- Richard Dean (ORCID: https://orcid.org/0009-0003-7438-8204)
- Lisa Forman (ORCID: https://orcid.org/0000-0002-4200-9359)
- Daniel S. Pratt (ORCID: https://orcid.org/0000-0002-7426-969X)
- Maryam Yazdanfar
- Cynthia Levy (ORCID: https://orcid.org/0000-0001-5498-6037)
- Fawzy Barry
- Usha Gungabissoon (ORCID: https://orcid.org/0000-0002-2040-1763)
- Michael Li (ORCID: https://orcid.org/0000-0003-0836-811X)
- Raghav Bordia
- Katherine Specht
- Isha J. Patel
- Duru Cosar
- Joseph Zepeda (ORCID: https://orcid.org/0009-0001-0484-6762)
Institutions
- University of Miami (US)
- Henry Ford Health System (US)
- Wayne State University (US)
- Henry Ford Hospital (US)
- Massachusetts General Hospital (US)
- University of Miami Health System (US)
- GlaxoSmithKline (United States) (US)
- University of California Davis Medical Center (US)
- Indiana University Indianapolis (US)
- Indiana University – Purdue University Indianapolis (US)
- University of San Francisco (US)
- University of California, Davis (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2026-08-17
- DOI
- https://doi.org/10.1111/apt.70931
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00